Immunological memory is a defining characteristic of Immunity, one that has allowed us to develop vaccines, some with the power to provide life-long immunity to pathogenic infectious diseases. While neutralizing antibodies have often been the focus of vaccination strategies, cell mediated protection, mainly in the form of cytotoxic CD8 T cells, also plays an important role in fighting many infections. CD8 T cells are crucial for killing infected cells, preventing the spread of pathogens, and even killing some cancer cells. Long-term CD8 T cell protection comes from memory CD8 T cells, which have a high proliferative capacity, can self renew, and respond almost immediately upon a secondary infection. However, the memory population is not uniform and at least two subsets can be identified, effector memory cell (TEM) and central memory cells (TCM). TCM have and increased capacity to self renew and proliferate, while TEM seem to have enhanced effector functions. Yet there is still a poor understanding of how these subsets develop and whether they represent different lineages or can interconvert in response to environmental signals. Given that memory cells can survive for decades it's important to understand the functional contribution of these subsets and how they are maintained. Previous work from our lab has shown that inflammatory signals can induce the transcription factor T-bet which modulates the potential of an effector CD8 T cell to become a memory cell by prompting the formation of short lived effector cells (SLECs) with reduced potential to form memory. We propose to investigate whether T-bet also plays a role in influencing the differention state of memory subsets through inflammatory signals in their environment. We will also further investigate how T-bet induces effector stage cells to terminally diferentiate. Understanding how CD8 Tcells acquire, or lose, memory characteristics is crucial for the development of more efficacious vaccines to protect from infectious diseases and potentially cancer. We plan on addressing these questions through the following aims:
Specific Aim 1; To determine whether the differentiation state of SLECs can be modulated by reducing T- bet, in the absence of antigen.
Specific Aim 2 : To determine if TEM and TCM memory CD8 T cell subsets interconvert and if T-bet is required for this process.
Specific Aim 3 : To determine if the transcription factor ZEB, a candidate target of T-bet, co-regulates the terminal differentiation of CD8 T cells.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Predoctoral Individual National Research Service Award (F31)
Project #
1F31AI084500-01
Application #
7754721
Study Section
Special Emphasis Panel (ZRG1-DKUS-D (29))
Program Officer
Adger-Johnson, Diane S
Project Start
2009-09-08
Project End
2012-09-07
Budget Start
2009-09-08
Budget End
2010-09-07
Support Year
1
Fiscal Year
2009
Total Cost
$41,176
Indirect Cost
Name
Yale University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Guan, Tianxia; Dominguez, Claudia X; Amezquita, Robert A et al. (2018) ZEB1, ZEB2, and the miR-200 family form a counterregulatory network to regulate CD8+ T cell fates. J Exp Med 215:1153-1168
Dominguez, Claudia X; Amezquita, Robert A; Guan, Tianxia et al. (2015) The transcription factors ZEB2 and T-bet cooperate to program cytotoxic T cell terminal differentiation in response to LCMV viral infection. J Exp Med 212:2041-56